Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
Neal D. Shore(Carolina Urologic Research Center), Raoul S. Concepcion(Integra (United States)), Emmanuel S. Antonarakis(University of Minnesota), Benjamin Lowentritt, Michael S. Cookson(University of Oklahoma Health Sciences Center), Jonathan Henderson(Regional Urology), J Spier(Rio Grande Council of Governments), Gordon Brown(New Jersey Urology), Alicia K. Morgans(Dana-Farber Cancer Institute), Daniel R. Saltzstein(Urology San Antonio), Richard G. Harris(Shriners Hospitals for Children), Jason Hafron(Beaumont Hospital, Royal Oak), David Albala(Baptist Health South Florida), E. David Crawford(Virginia Commonwealth University)
Cited by 64
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k